As of 2024-09-18, the EV/EBITDA ratio of Blueprint Medicines Corp (BPMC) is -16.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BPMC's latest enterprise value is 5,812.55 mil USD. BPMC's TTM EBITDA according to its financial statements is -344.09 mil USD. Dividing these 2 quantities gives us the above BPMC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 17.3x | 15.0x |
| Forward P/E multiples | 16.4x - 26.7x | 20.2x |
| Fair Price | (94.43) - (99.21) | (100.97) |
| Upside | -209.2% - -214.7% | -216.7% |
| Date | EV/EBITDA |
| 2024-09-18 | -17.41 |
| 2024-09-17 | -16.89 |
| 2024-09-16 | -16.85 |
| 2024-09-13 | -17.33 |
| 2024-09-12 | -16.45 |
| 2024-09-11 | -16.90 |
| 2024-09-10 | -16.80 |
| 2024-09-09 | -16.90 |
| 2024-09-06 | -16.88 |
| 2024-09-05 | -17.79 |
| 2024-09-04 | -18.02 |
| 2024-09-03 | -18.00 |
| 2024-08-30 | -18.56 |
| 2024-08-29 | -18.20 |
| 2024-08-28 | -18.04 |
| 2024-08-27 | -18.11 |
| 2024-08-26 | -18.47 |
| 2024-08-23 | -18.37 |
| 2024-08-22 | -18.18 |
| 2024-08-21 | -18.42 |
| 2024-08-20 | -18.12 |
| 2024-08-19 | -18.58 |
| 2024-08-16 | -18.18 |
| 2024-08-15 | -18.55 |
| 2024-08-14 | -18.15 |
| 2024-08-13 | -18.05 |
| 2024-08-12 | -18.22 |
| 2024-08-09 | -18.25 |
| 2024-08-08 | -17.80 |
| 2024-08-07 | -17.69 |
| 2024-08-06 | -18.04 |
| 2024-08-05 | -18.08 |
| 2024-08-02 | -18.77 |
| 2024-08-01 | -19.43 |
| 2024-07-31 | -20.90 |
| 2024-07-30 | -20.67 |
| 2024-07-29 | -21.28 |
| 2024-07-26 | -21.62 |
| 2024-07-25 | -21.90 |
| 2024-07-24 | -22.13 |
| 2024-07-23 | -22.50 |
| 2024-07-22 | -22.47 |
| 2024-07-19 | -22.13 |
| 2024-07-18 | -21.85 |
| 2024-07-17 | -22.02 |
| 2024-07-16 | -23.15 |
| 2024-07-15 | -22.97 |
| 2024-07-12 | -22.65 |
| 2024-07-11 | -22.65 |
| 2024-07-10 | -22.31 |